Immunome (IMNM) Income Statement: Revenue & Earnings

Immunome Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Immunome, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	9.04	14.02	0.00	0.00	0.00
Cost of Revenue	0.00	23.09	23.11	0.00	0.00
Gross Profit	9.04	-9.07	-23.11	0.00	0.00
Operating Expenses
Research & Development	129.54	23.09	23.27	14.11	7.49
Selling, General & Administrative	32.96	19.66	13.63	11.09	4.78
Operating Expenses	162.50	19.66	36.90	25.20	12.26
Operating Income	-153.46	-28.73	-36.90	-25.20	-12.26
Other Income/Expense
Interest Income	12.84	2.72	0.01	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.01	-0.04
Other Income/Expense	-152.34	-80.80	0.62	0.50	5.50
Income
Income Before Tax	-292.96	-106.81	-36.90	-24.71	-17.80
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-292.96	-106.81	-36.90	-24.71	-17.84
Net Income - Continuous Operations	-292.96	-106.81	-36.90	-24.71	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-151.35	-28.27	-36.27	-24.45	-17.04
EBIT	-153.46	-28.73	-36.90	-25.20	-17.80
Depreciation & Amortization	2.10	0.46	0.40	0.76	0.80
Earnings Per Share
Basic EPS	-5.00	-5.00	-3.00	-2.00	-5.00
Diluted EPS	-5.00	-5.00	-3.00	-2.00	-5.00
Basic Shares Outstanding	58.64	19.84	12.13	11.54	3.39
Diluted Shares Outstanding	58.64	19.84	12.13	11.54	3.39